Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Clinical value of ALK and CD30 expression in mature systemic T cell lymphomas: analysis from the Czech Lymphoma Study Group database (NIHIL)

A. Janikova, J. Michalka, R. Chloupkova, N. Kopalova, V. Campr, K. Kamaradova, L. Kren, D. Belada, K. Benesova, J. Dlouha, P. Klener, V. Procházka, H. Mocikova, J. Duras, M. Trneny

. 2022 ; 101 (4) : 789-798. [pub] 20220121

Language English Country Germany

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22010693

Grant support
NU21-03-00611 ministerstvo školství, mládeže a tělovýchovy

Mature T cell lymphomas MTCLs have worse prognosis and in contrast to B cell lymphomas there is no universal marker like CD20 with exception of ALK and CD30 which are present in proportion of MTCL only Up to now ALK is traditionally associated with good prognosis in ALCLs and there are some evidences that CD30 positive T cell or B cell lymphomas have better prognosis In our retrospective

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22010693
003      
CZ-PrNML
005      
20250424111347.0
007      
ta
008      
220425s2022 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00277-022-04759-1 $2 doi
035    __
$a (PubMed)35061088
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Janikova, A $u Department of Internal Medicine - Hematology and Oncology, Masaryk University and University Hospital Brno, Jihlavska 20, 62500, Brno, Czech Republic. janikova.andrea@fnbrno.cz $1 https://orcid.org/0000000226477769 $7 xx0103433
245    10
$a Clinical value of ALK and CD30 expression in mature systemic T cell lymphomas: analysis from the Czech Lymphoma Study Group database (NIHIL) / $c A. Janikova, J. Michalka, R. Chloupkova, N. Kopalova, V. Campr, K. Kamaradova, L. Kren, D. Belada, K. Benesova, J. Dlouha, P. Klener, V. Procházka, H. Mocikova, J. Duras, M. Trneny
520    9_
$a Mature T cell lymphomas (MTCLs) have worse prognosis, and in contrast to B cell lymphomas, there is no universal marker like CD20 with exception of ALK and CD30, which are present in proportion of MTCL only. Up to now, ALK is traditionally associated with good prognosis in ALCLs, and there are some evidences that CD30-positive T cell or B cell lymphomas have better prognosis. In our retr $a Mature T cell lymphomas (MTCLs) have worse prognosis, and in contrast to B cell lymphomas, there is no universal marker like CD20 with exception of ALK and CD30, which are present in proportion of MTCL only. Up to now, ALK is traditionally associated with good prognosis in ALCLs, and there are some evidences that CD30-positive T cell or B cell lymphomas have better prognosis. In our retrospective, population-based analysis, we analyzed the real clinical value of ALK and CD30 in the most frequent MTCL subtypes. Between 2000 and 2017, we identified 732 patients with newly diagnosed ALCL, AITL, or PTCL-NOS. Among them, 207 ALCL patients were with known ALK, whereas 61 AITL and 238 PTCL-NOS with known CD30 expression. There were 69/207 (33.3%) ALK + ALCLs, who displayed better 5-year PFS (65.6% vs. 36.2%) (p .001) and 5-year OS (71.5% vs. 45.9%) (p .002) compared to ALK - ; ALK + patients were significantly younger (median 48 vs. 60 years; p < 0.001). For patients ≥ 60 years, 5-year PFS (38.5% vs. 31.2%) and 5-year OS (38.5% vs. 39.6%) were similar between ALK + vs. ALK - patients. For AITL and PTCL-NOS, there were 44/61 (72.1%) and 120/238 (50.4%) CD30 + samples, and difference in CD30 expression was significant (p .02). AITL patients had 5-year OS of 43.8% vs. 55.7% (p 0.848) and 5-year PFS of 36.7% vs. 29.4% (p .624) for CD30 + vs. CD30 - patients, whereas PTCL-NOS had 5-year OS of 35.7% vs. 34.3% (p .318) and 5-year PFS of 29.3% vs. 22.5% (p.114) for CD30 + vs. CD30 - cases. We conclude that ALK in ALCLs (≥ 60 years) and CD30 expression in PCTL-NOS and AITL have only limited prognostic value. $a Mature T cell lymphomas MTCLs have worse prognosis and in contrast to B cell lymphomas there is no universal marker like CD20 with exception of ALK and CD30 which are present in proportion of MTCL only Up to now ALK is traditionally associated with good prognosis in ALCLs and there are some evidences that CD30 positive T cell or B cell lymphomas have better prognosis In our retrospective
650    _2
$a lidé $7 D006801
650    12
$a antigen Ki-1 $7 D017730
650    12
$a periferní T-buněčný lymfom $x patologie $7 D016411
650    _2
$a prognóza $7 D011379
650    _2
$a tyrosinkinasové receptory $7 D020794
650    _2
$a retrospektivní studie $7 D012189
651    _2
$a Česká republika $7 D018153
655    _2
$a časopisecké články $7 D016428
700    1_
$a Michalka, J $u Department of Internal Medicine - Hematology and Oncology, Masaryk University and University Hospital Brno, Jihlavska 20, 62500, Brno, Czech Republic
700    1_
$a Chloupkova, R $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Kopálová, Nataša $u Department of Internal Medicine - Hematology and Oncology, Masaryk University and University Hospital Brno, Jihlavska 20, 62500, Brno, Czech Republic $7 xx0331481
700    1_
$a Campr, V $u Department of Pathology and Molecular Medicine, 2nd Faculty of Medicine, Charles University and Faculty Hospital in Motol, Prague, Czech Republic
700    1_
$a Kamaradova, K $u The Fingerland Department of Pathology, Charles University Hospital and Faculty of Medicine, Hradec Králové, Czech Republic
700    1_
$a Kren, L $u Department of Pathology, Masaryk University and University Hospital Brno, Brno, Czech Republic
700    1_
$a Belada, D $u 4Th Department of Internal Medicine - Hematology, Charles University Hospital and Faculty of Medicine, Hradec Králové, Czech Republic
700    1_
$a Benesova, K $u 1St Department of Medicine, First Medical Faculty, Charles University and General University Hospital, Prague, Czech Republic
700    1_
$a Dlouha, J $u 1St Department of Medicine, First Medical Faculty, Charles University and General University Hospital, Prague, Czech Republic
700    1_
$a Klener, P $u 1St Department of Medicine, First Medical Faculty, Charles University and General University Hospital, Prague, Czech Republic
700    1_
$a Procházka, V $u Department of Hematology, University Hospital Olomouc, Olomouc, Czech Republic
700    1_
$a Mocikova, H $u Internal Clinic of Haematology, University Hospital Kralovske Vinohrady, Prague, Charles University in Prague, 3Rd Faculty of Medicine, Prague, Czech Republic
700    1_
$a Duras, J $u Department of Clinical Hematology, Teaching Hospital Ostrava, Ostrava, Czech Republic
700    1_
$a Trneny, M $u 1St Department of Medicine, First Medical Faculty, Charles University and General University Hospital, Prague, Czech Republic
773    0_
$w MED00000424 $t Annals of hematology $x 1432-0584 $g Roč. 101, č. 4 (2022), s. 789-798
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35061088 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20250424111346 $b ABA008
999    __
$a ok $b bmc $g 1788709 $s 1161891
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 101 $c 4 $d 789-798 $e 20220121 $i 1432-0584 $m Annals of hematology $n Ann Hematol $x MED00000424
GRA    __
$a NU21-03-00611 $p ministerstvo školství, mládeže a tělovýchovy
LZP    __
$a Pubmed-20220425

Find record

Citation metrics

Archiving options